Features Partner Sites Information LinkXpress
Sign In
Demo Company

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

By BiotechDaily International staff writers
Posted on 16 Jun 2014
Print article
Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now.

The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals was not uniform among the constituent sectors, with the biotechnology, pharmaceutical, and healthcare equipment sectors experiencing a much sharper decline in investor interest than the healthcare technology and provider segments. Investors began to gamble on providers based with the conviction they can provide faster and safer returns than the pharmaceutical and biotechnology space, which is ridden with regulatory challenges and patent expiries.

A new market analysis from Frost & Sullivan’s (Mountain, View, CA, USA), an international growth consultancy firm, revealed the total number of PEVC transactions in the pharmaceutical and biotechnology industry decreased from 1063 in 2010 to 480 in 2013. Although the returns from the pharmaceutical and biotechnology industry have been declining, they are better compared to the performance of other industries.

“PE deals in the pharmaceutical sector have been relatively stable over the post-recession period whereas activity in the biotechnology segment began to decrease after reaching its peak in 2010, due to the uncertainty caused by healthcare reform in the US, long incubation periods, and delayed approvals,” said Frost & Sullivan financial analyst Dr. E. Saneesh. “VC deals across both these sectors also started to plummet from 2011 due to risks associated with regulatory uncertainty, long gestation periods, and increased cost of production.”

However, the strong rebirth of initial public offerings (IPOs) in 2013 indicates a positive outlook for investment in the pharmaceutical and biotechnology industry. The number of IPOs in the global biotechnology sector surged by 100% between 2012 and 2013, primarily on account of the 26 IPOs that took place in the United States. IPOs in the pharmaceutical industry also climbed with 11 deals in 2013, after the volume of IPOs declined to nearly one-sixth of the sector’s value between 2011 and 2012.

As a result of the surge in IPOs, exit opportunities are expected to increase for investors. The trend will be further fuelled by the anticipated growth of corporate investor-backed IPOs. “PEVC investors in the global pharmaceutical and biotechnology industry have demonstrated maximum interest in oncology drugs, followed by anti-infective drugs and pharmaceutical contract laboratories,” stated Dr. Saneesh. “They have also concluded the maximum pharmaceutical- and biotechnology-related PEVC deals in the US and are expected to continue to do so in the forthcoming years. Industry players most aligned with these trends will be well positioned to obtain financial support from PEVC investors.”

Related Links:

Frost & Sullivan

Print article



view channel
Image: Left: Green actin fibers create architecture of the cell. Right: With cytochalasin D added, actin fibers disband and reform in the nuclei (Photo courtesy of the University of North Carolina).

Actin in the Nucleus Triggers a Process That Directs Stem Cells to Mature into Bone

A team of cell biologists has discovered why treatment of mesenchymal stem cells (MSCs) with the mycotoxin cytochalasin D directs them to mature into bone cells (osteoblasts) rather than into fat cells... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more

Lab Technologies

view channel
Image: The new ambr 15 fermentation micro-bioreactor system was designed to enhance microbial strain screening applications (Photo courtesy of Sartorius Stedim Biotech).

New Bioreactor System Streamlines Strain Screening and Culture

Biotechnology laboratories working with bacterial cultures will benefit from a new automated micro bioreactor system that was designed to enhance microbial strain screening processes. The Sartorius... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.